DIVA: Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein graft Angioplasty
Principal Investigator: Anand Irimpen, MD
Sponsor: VA Office of Research and Development
ClinicalTrials.gov - NCT01121224

RELAX-AHF-2: A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients
Principal Investigator: Thierry Le Jemtel, MD
Sponsor: Novartis Pharmaceuticals
ClinicalTrials.gov - NCT01870778

REDUAL-PCI: A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting
Principal Investigator: Anand Irimpen, MD
Sponsor: Boehringer-Ingelheim
ClinicalTrials.gov - NCT02164864

RE-CIRCUIT: Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation
Principal Investigator: Colleen Johnson, MD
Sponsor: Boehringer-Ingelheim
ClinicalTrials.gov - NCT02348723

ORBIT-AF II - Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
Principal Investigator: Anand Irimpen, MD
Sponsor: Janssen-Scientific
ClinicalTrials.gov - NCT01701817

GARFIELD-AF: Prospective, multi center, international registry of male and female patients newly diagnosed with atrial fibrillation
Principal Investigator: Keith Ferdinand, MD
Sponsor: London Thrombosis Institute
ClinicalTrials.gov - NCT01090362
GARFIELD-VTE: Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world
Principal Investigator: Gholam Ali, MD
Sponsor: London Thrombosis Institute
ClinicalTrials.gov - NCT02155491

USpella: Impella 2.5, Impella 5.0, Impella LD and Impella CP Data Registry
Principal Investigator: Nidal Abi Rafeh, MD
Sponsor: Abiomed, INC

ODYSSEY-OUTCOMES: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary
Principal Investigator: Alvaro Alonso MD
Sponsor: Sanofi
ClinicalTrials.gov - NCT01663402

CANTOS-A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated
Principal Investigator: Keith Ferdinand, MD
Sponsor: Novartis
ClinicalTrials.gov - NCT01327846